GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Interest Expense

CTOR (Citius Oncology) Interest Expense : $ Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Citius Oncology's interest expense for the six months ended in Sep. 2024 was $ 0.00 Mil. Citius Oncology does not have enough years/quarters to calculate its interest expense for the trailing twelve months (TTM) ended in Sep. 2024.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Citius Oncology's Operating Income for the six months ended in Sep. 2024 was $ -20.57 Mil. Citius Oncology's Interest Expense for the six months ended in Sep. 2024 was $ 0.00 Mil. GuruFocus does not calculate Citius Oncology's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Citius Oncology Interest Expense Historical Data

The historical data trend for Citius Oncology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Interest Expense Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Interest Expense
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Interest Expense - - -

Citius Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Citius Oncology  (NAS:CTOR) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Citius Oncology's Interest Expense for the six months ended in Sep. 2024 was $0.00 Mil. Its Operating Income for the six months ended in Sep. 2024 was $-20.57 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Sep. 2024 was $3.80 Mil.

Citius Oncology's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

GuruFocus does not calculate Citius Oncology's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Citius Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Interest Expense
Comparable Companies
SCYX RMTI SXTC MRMD ETST CPIX ASRT INCR INIS DRRX ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XSWX:SDZ HKSE:03692 NSE:DIVISLAB XTAE:TEVA
Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Website
https://www.citiusonc.com
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.